Stock Screener App

Gratuito -

1.75

5.78% +0.0957

Dopo l'orario di chiusura: 1.74 -0.01 -0.57%

Processa Pharmaceuticals Inc (PCSA)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Processa Pharmaceuticals Inc Borsa (PCSA) Ultime notizie

Processa Pharmaceuticals (NASDAQ:PCSA) Given “Buy” Rating at HC Wainwright - Defense World

Processa Pharmaceuticals Inc [PCSA] Investment Guide: What You Need to Know – Knox Daily - Knox Daily

Processa reports positive Phase 1b trial results for cancer drug By Investing.com - Investing.com

Processa Pharmaceuticals Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle

The InvestChronicle

Understanding PCSA's financial ratios: A beginner's guide – US Post News - US Post News

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference - Barchart

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

GlobeNewswire Inc.

FDA Review of MDMA as PTSD Drug Exposes Flawed Process - Bloomberg

Suraksha Group finally takes over Jaypee Infratech via insolvency process - Business Standard

Business Standard

Financial Health Report: Processa Pharmaceuticals Inc (PCSA)'s Ratios Tell a Tale – DWinneX - The Dwinnex

5 Best-Performing Biotech Stocks for June 2024 - NerdWallet

Ulcerated Necrobiosis Lipoidica Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024 ... - openPR

NovaBay Pharmaceuticals Stock Is Up 50%: What's Going On? - NovaBay Pharmaceuticals (AMEX:NBY) - Benzinga

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Forecasted to Post Q2 2024 Earnings of ($0.98) Per Share - Defense World

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Forecasted to Post Q2 2024 Earnings of ($0.98) Per Share - Defense World

Processa Pharmaceuticals (NASDAQ:PCSA) Rating Reiterated by HC Wainwright - Defense World

HC Wainwright Comments on Processa Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:PCSA) - Defense World

Processa Pharmaceuticals Inc expected to post a loss of $1.18 a share - Earnings Preview - XM

Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly - CNBC

IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer - OncLive

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

GlobeNewswire Inc.

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research - citybiz

Spotting Penny Stocks Uptrends, 3 Top Tips

Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Alphabet (NASDAQ:GOOGL) - Benzinga

Intent of global acquisitions, has the tide turned for the long term? 5 pharma stocks with upside potentia - The Economic Times

The Economic Times

Refreshed Drug Discount Dispute Process to Face Wave of Claims - Bloomberg Law

Americans Are Paying Billions to Take Drugs That Don't Work - Bloomberg

PCSA's short interest shows a sharp decline on Mar 15, 2024 – Knox Daily - Knox Daily

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.09% By Investing.com - Investing.com

Processa Pharmaceuticals Insiders Still US$40k Away From Original Investment Value - Simply Wall St

Insider Buyers At Processa Pharmaceuticals Recover Some Losses, But Still Down US$40k - Yahoo Finance

Acorda Therapeutics Announces Nasdaq Delisting Notification - Yahoo Finance

Processa Pharmaceuticals' Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks - TipRanks.com - TipRanks

Processa Pharmaceuticals' Future in Jeopardy: A Dive into Its Financial Crisis and Industry Risks - TipRanks.com - TipRanks

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

GlobeNewswire Inc.

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

GlobeNewswire Inc.

Integrated Continuous Manufacturing in Pharmaceuticals - CHEManager

FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy - OncLive

Drug Clashes Continue Amid Crackdown on Registry Patent Listings - Bloomberg Law

Small-cap stock below ₹10: Pharma stock Vikas Lifecare hits upper circuit after getting new patent | Stock Market News - Mint

VRTX: Jumpstart Your Portfolio With These 3 Biotech Stocks - StockNews.com

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire Inc.

OCS Stock Quote Price and Forecast - CNN

United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings - Yahoo Finance

REGN Stock Quote Price and Forecast - CNN

Aurinia to cut research after sale process fails to find a buyer - Yahoo Finance

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

GlobeNewswire Inc.

Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying

Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying - Abeona Therapeutics (NASDAQ:ABEO) - Benzinga

Processa Pharmaceuticals Secures NASDAQ Listing Compliance - TipRanks.com - TipRanks

$83.51

0.87%

$26.19

0.83%

$162.58

2.28%

$160.39

0.21%

$92.08

4.08%

$387.00

0.35%

Apri su Yahoo | Apri su Google | Aperto in Finviz